Artiva Biotherapeutics (ARTV) Current Assets (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Current Assets data on file, last reported at $88.7 million in Q1 2026.

• On a quarterly basis, Current Assets fell 47.8% year-over-year to $88.7 million in Q1 2026; TTM through Mar 2026 was $88.7 million, a 47.8% decrease from a year earlier, with the FY2025 full-year figure at $112.7 million, down 40.27% from the prior year.
• Current Assets for Q1 2026 stood at $88.7 million, down from $112.7 million in the prior quarter.
• Over the last five years, Current Assets for ARTV reached as high as $188.6 million in Q4 2024 and fell as low as $49.7 million in Q2 2024.
• Historically, Current Assets has averaged $124.3 million across 4 years, with a median of $129.5 million in 2025.
• Across the five-year window, Current Assets surged 199.64% in 2025 and sank 47.8% in 2026, its largest moves.
• Year by year, Current Assets stood at $79.8 million in 2023, then surged by 136.32% to $188.6 million in 2024, then plunged by 40.27% to $112.7 million in 2025, then retreated by 21.24% to $88.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $88.7 million in Q1 2026, $112.7 million in Q4 2025, and $129.5 million in Q3 2025.